P
eripheral arterial disease (PAD) affects ≈12% to 20% of the population, with an age-adjusted prevalence of 4% to 15%, which increases up to 29% in presence of cardiovascular risk factors. 1 The mainstay of therapy includes risk factor modification, exercise, and antiplatelet therapy with optional revascularization. Given the lower risk of periprocedural complications as compared with vascular surgery, endovascular therapy is generally preferred as the first choice for symptomatic patients with PAD involving the femoropopliteal arteries. Unlike most other vascular beds, where stenting is the preferred modality for percutaneous revascularization, the optimal therapy for superficial femoral artery (SFA) disease remains controversial. Guidelines from the American College of Cardiology/American Heart Association and Trans-Atlantic Inter-Society Consensus for the management of PAD recommend plain balloon angioplasty (BA) as the initial preferred treatment of symptomatic SFA lesions, reserving provisional stenting as salvage therapy in case of suboptimal acute results or failure after balloon dilation. 2 However, the evolution of endovascular therapies has inspired an ongoing debate over the relative merits of available percutaneous therapies. A primary stenting avoids the problems of early elastic recoil, residual stenosis, and flow-limiting dissections frequently observed with BA alone and can be used for treatment of long calcified lesions. Accordingly, clinical studies have shown the superiority of stenting versus BA in long SFA lesions, 1,2 whereas in short lesions (<10 cm in length) no differences between primary and provisional stenting were detected. 3 However, the SFA is subject to longitudinal stretching, external compression, torsion, and flexion that may lead to stent fractures and eventually restenosis. Previous meta-analyses showed no significant differences in the rate of target vessel revascularization between BA with provisional stenting and primary stenting for symptomatic patients with short SFA lesions, although a trend towards lower restenosis and a significant higher immediate success in favor of routine stenting were observed. 4, 5 Recent studies have shown that iterations in stent material and design may improve clinical outcomes. [6] [7] [8] In addition, endovascular therapies alternative to BA or stenting have recently attracted considerable interest. Paclitaxel-eluting stents displayed sustained safety and efficacy compared with BA in patients with femoral artery disease, with superior clinical efficacy as compared to BA and provisional stenting. 9 Paclitaxel-coated balloon angioplasty for atherosclerotic femoropopliteal disease reduces target-lesion revascularization as compared with BA with the advantage of leaving no prosthetic material behind. [10] [11] [12] However, complex femoropoliteal lesions may require mechanical scaffolding to prevent elastic recoil and occlusive dissections. Therefore, the combination of PEB angioplasty and stenting might represent a valuable antirestenotic therapy. 13 The plaque removal with directional atherectomy (DA) represents an alternative percutaneous option with favorable acute technical success. Previous studies of DA showed its feasibility in the treatment of SFA lesions and low target vessel revascularization rates. [14] [15] [16] [17] De novo lesions appear to benefit more than restenostic lesions. 16 A meta-analysis showed that DA of the femoropopliteal artery does not improve clinical outcomes over BA. 18 To date, there is no randomized trial investigating the safety and the efficacy of PEB and stenting versus BA and stenting versus DA for patients suffering from atherosclerotic SFA disease. Therefore, we performed a randomized controlled trial to compare PEB angioplasty and stenting versus BA and stenting versus DA and bailout stenting in patients with femoropopliteal artery disease due to de novo atherosclerotic lesions.
METHODS STUDY POPULATION
The ISAR-STATH trial (Intravascular Stenting and Angiographic Results: A randomized trial comparing paclitaxel-eluting balloon angioplasty plus stenting versus standard balloon angioplasty plus stenting versus directional atherectomy for symptomatic femoral artery disease) was a prospective, randomized, active-controlled, open label trial at 2 centers designed to compare PEB angioplasty and stenting versus BA and stenting versus DA for SFA de novo lesions in patients with intermittent claudication. It was approved by the institutional review ethics committee (Ethikkomission der Medizinischen Fakultät der Technischen Universität München) and was carried out in accordance with the Helsinki declaration. All patients provided written informed consent.
Angiographic inclusion criteria were de novo stenosis >70% or occlusion of the SFA. Exclusion criteria were acute ischemia or acute thrombosis of the SFA, untreated ipsilateral iliac artery stenosis >70%, previous stenting of the SFA, popliteal stenosis >70%, severe renal insufficiency (estimated
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• In this randomized controlled trial, treatment of de novo superficial femoral artery lesions paclitaxeleluting balloon angioplasty and stenting is superior to plain balloon angioplasty and stenting or directional atherectomy regarding angiographic diameter stenosis at 6 months and target lesion revascularization at 24 months.
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glomerular filtration rate <30 mL/minute/1.73m
2 ), life expectancy of <1 year, and contraindication to required medications. Allocation to treatment was made by means of sealed, opaque envelopes containing a computer-generated sequence after decision to proceed with the intervention. Patients who met all of the inclusion criteria and none of the exclusion criteria were randomized in a 1:1:1 ratio.
STUDY INTERVENTION
Crossover or antegrade approach was chosen as appropriate. The intraluminal crossing was achieved using a 0.014-inch guide wire (ASAHI ConfianzaPro12) and a support catheter (4-Fr Berenstein). If intraluminal passage was not possible, then a small dissection reentry technique was applied with a 0.035 Terumo wire. Once the wire was in the distal lumen, the patients were randomized and the assigned treatment performed in all patients. Predilatation with a vessel-to-balloon diameter ratio of 1:1 was achieved with a standard balloon in both groups undergoing angioplasty. In the group of stenting after PEB angioplasty, additional dilation with a PEB (In.PACT Admiral, Invatec/ Medtronic) for 2 minutes maintaining a vessel-to-balloon diameter of 1:1 was done just before stenting. All patients in the stent groups, received a nitinol stent exceeding the nominal vessel diameter by 1 mm (Smart Stent, Cordis, Johnson & Johnson). The stent length exceeded the lesion length by 5 mm proximal and distal. A second stent was deployed when 1 stent did not cover the whole lesion or residual dissections extended beyond the stent margins. Treatment with PEB always covered the complete lesion. Subsequent stenting covered the entire PEB-treated lesion. Stenting after dilation was performed after PEB angioplasty and BA using conventional balloons. In the DA group, after passage of the wire, a Spider Filter (SPIDER Embolic Protection EV3 Inc/Fox Hollow Technologies) was deployed in the popliteal artery for distal protection. DA was performed using the SilverHawk plaque excision system (Covidien). If angiography after DA showed residual stenosis of >50% or flow-limiting dissections, then inflation with a conventional balloon was performed (1:1 vessel-to-balloon ratio) for 1 minute at low pressure. A nitinol stent was implanted in lesions with persistent residual stenosis >50% or in the presence of flow-limiting dissections. Technical success was defined as residual stenosis <30% by final angiography. Immediately after the decision to perform the intervention, patients were given 500 mg aspirin intravenously (if they did not receive it within the previous 12 hours) and 5000 U intra-arterial heparin. After the intervention, all patients received aspirin 100 mg per day indefinitely and clopidogrel 75 mg per day for ≥6 months.
All patients were evaluated at 6 and 24 months by phone or office visit. A repeat angiography was scheduled at 6 to 8 months. The local research coordinators collected the data and forwarded them to the independent core labs Clinical Data Management Center and QCA laboratory (ISARESEARCH Center). Data quality was ensured by checking source documentation.
STUDY END POINTS
The primary end point of the study was the diameter stenosis as measured by angiography at 6 months. The first angiogram (at the time of randomization) as well as the repeat angiogram (primary end point evaluation) were performed in identical projections and sent to the Imaging Core Laboratory to be quantitatively evaluated. The target lesion was identified by the vascular anatomy and bone landmarks. The angiographic imaging of the target lesion was done in accordance with QVA Core Laboratory guidelines. Quantitative analysis was performed in the intervened or in-segment area, including the stented/atherectomized segment, as well as both 5 mm areas proximal and distal to the stent margins (in-segment analysis). Secondary end points were binary restenosis frequency (defined as >50% diameter stenosis as measured by angiography at 6 months), target lesion revascularization (TLR) at 24 months, time to the onset and incidence of peripheral vascular events (incidence of amputation, revascularization, or bypass surgery) at 24 months, and all-cause mortality at 24 months. All TLRs were clinically driven and confirmed angiographically before treatment.
STATISTICAL ANALYSIS
The sample size calculation was based on the following assumptions regarding the primary end point: % diameter stenosis of 36% after BA+stent, 28% after DA, and 20% after PEB+stent with equal variance (SD of 20%), a 2-sided alpha level of 0.017 accounting of three 2-group comparisons and a power of 80%. The sample size calculation was performed based on analysis of variance with the use of NQuery 7.0. This resulted in a number of 43 patients needed per group. To compensate for possible missing angiogragrams and patient withdrawals, 150 patients were planned to be included. Continuous data are presented as mean±standard deviation. Categorical data are presented as counts or proportions (%). Data distribution was tested for normality using the Kolmogorov-Smirnov test for goodness of fit. Differences between the groups were analyzed using Student's t test or Wilcoxon rank sum test (continuous data) or χ-squared for categorical data (or Fisher exact test where the expected cell value was <5). Event-free survival was assessed using the methods of Kaplan-Meier and comparisons performed with the log-rank test. A 2-sided P-value of <0.017 was considered to indicate statistical significance. Statistical software IBM SPSS version 22 (IBM Corp.) was used for analysis. IO, KD, and AK had full access to all the data in the study and take responsibility for its integrity and the data analysis.
RESULTS
Between July 2009 and November 2013, 499 patients with symptomatic de novo femoropoliteal disease (Rutherford classification from 2-6) were treated in both centers. Mean age was 71 years with 31% females, 73% of the patients had hypertension, 33% had diabetes mellitus, 60% were smokers, and 50% suffered from coronary heart disease. After passage of the guide wire, 155 patients were enrolled and randomized to receive either PEB angioplasty followed by stent (n=48) or BA followed by stent (n=52) or DA (n=55). Patients were comparable in their baseline characteristics except more patients in the DA group suffered from coronary artery disease (Table 1). Lesion length was relatively short (65.9 mm) but similar in all groups; however, the degree of angiographically measured stenosis was the highest in the group of patients receiving PEB followed by stent. Most of the lesions were complex and moderate to severe calcified. In patients suffering from occlusions, intraluminal passage was not possible in 62% of the cases.
All patients received the randomly assigned treatment. In the DA group, 14 patients received bail-out stenting due to flow-limiting dissections, 1 patient received a covered stent to seal a vessel perforation, 1 suffered from perforation treated by prolonged balloon inflation and protamine administration. One patient in the DA group required stenting because of flow-limiting dissection and developed thrombus after stent implantation that was treated successfully by thrombus aspiration. The number of stents implanted was comparable in patients receiving PEB angioplasty followed by stent and BA angioplasty followed by stent (1.3±0.8 versus 1.4±0.6, P=0.43). Maximum balloon size after dilation was comparable in both groups after stenting but lower by trend in the DA group (Table 2) .
Six-month follow-up angiography was performed in 116 (75%) patients (Figure 1 ). Twenty-seven patients refused angiography because of lack of complaints, and in 11 patients angiography was not performed because of other reasons (eg, lost to follow-up, renal insufficiency that allows no contrast exposure, other medical problems). The key characteristics in patients with and without 6-month angiography showed no significant differences (Table I in the online-only Data Supplement). Angiographic outcomes are shown in Table 3 . The primary end point of the study-angiographic diameter stenosis after 6 months-was significantly lower in patients receiving PEB angioplasty and stenting (34±31%) as compared with BA and stenting (56±29%, P=0.009) or DA (55±29%, P=0.007). Similarly, binary restenosis and late lumen loss were lower after PEB and stenting as compared with BA and stenting or DA (Table 3 ). In addition, we analysed whether the treatment effect for the primary end point was influenced from the presence of vessel occlusion at baseline angiography (Table  II in the online-only Data Supplement). We found no association between the presence of vessel occlusion at baseline angiography and the treatment effect observed for the diameter stenosis after 6 months. The lower diameter stenosis after treatment with PEB and stenting did not translate into improved clinical outcomes after 6 months but after 24 months (Table 4) . Indeed, TLR after 6 months was numerically lower after PEB and stenting as compared with DA, though this result did not reach statistical significance.
Clinical follow-up after 24 months was performed in 115 (74%) patients. Mean clinical follow-up was comparable in all groups (PEB and stenting 26 months, BA and stenting 26 months, and DA 23 months). After 24 months, TLR was significantly decreased after PEB and stenting versus BA and stenting ( Figure 2 ). TLR was achieved in all patients by interventional procedures, and no amputation or bypass surgery was required in any group. Interestingly, the rate of target vessel thrombosis was the highest in the patients treated by PEB and stenting as compared with BA and stenting, although not statistically significant (Table 4) . Target vessel thrombosis occurred in 3 patients at 11, 38, and 48 days. In these patients, thrombosis was successfully treated by thrombus aspiration and stenting. Mortality after 6 and 24 months was not statistically different between groups, athough the analyses were limited by the extremely low number of events. One death occurred in a patient in the PEB and stenting group 1 day after the procedure because of hemorrhagic shock caused by severe retroperitoneal bleeding. After 24 months, 2 patients died in the PEB and stenting group and 1 patient in the BA and stenting group as a result of underlying cardiac disease (Table 4) .
DISCUSSION
This study is the first prospective randomized comparison of treatment with PEB and stenting or BA and stenting or DA in patients with symptomatic peripheral artery disease due to de novo superficial femoral artery stenosis. The main findings are: (1) a therapeutic option of PEB and stenting was superior with regard to 6-month diameter stenosis to BA and stenting and DA in de novo lesions of the SFA, and (2) TLR after 24 months was significantly lower after treatment with PEB and stenting as compared with the other 2 groups. This benefit is likely attributable to reduction of neointima formation by PEB angioplasty as a result of the antiproliferative effect of the paclitaxel. This finding was corroborated by the significant reduction in angiographic restenosis 6 months after PEB and stenting. The significant reduction of restenosis by pretreatment with Figure 1 . Patient flow chart.
Enrollment by original random assignments, death (all-cause), and lost to follow-up through 6 months are shown. BA indicates balloon angioplasty; DA, directional atherectomy; PEB, paclitaxel-eluting balloon; and SFA, superficial femoral artery. PEB angioplasty also suggests that smooth muscle cell hyperplasia plays a central role in lumen renarrowing after stenting of the superficial femoral artery. The findings of this trial further support a broader indication for PEB angioplasty in patients with femoropopliteal disease as a pretreatment option before stenting. After treatment with PEB angioplasty and stenting, the stent thrombosis rate was numerically increased as compared with BA and stenting. Stent underexpansion may contribute to stent thrombosis; however, similar vessel diameters were observed in the BA and stenting group. Further studies are required to analyze this finding and address potential underlying mechanisms. In this study, DA was associated with lower efficacy as compared with PEB and stenting. The high frequency of SFA occlusions included in the study and the inability to cross all lesions intraluminally may contribute to the high rate of bailout stenting and potentially worse clinical outcomes after DA. Moreover, perforation, a known potential complication of DA, was observed in our study in 2 cases. However, previous reports described the incidence of perforation with DA as high as to 10.5%, 19 yet all cases could be managed percutaneously. Whether the synergy between PEB angioplasty and DA may further reduce restenosis and improve long-term clinical outcomes deserves dedicated investigations. 20 Follow-up angiography rates in our study are comparable to those reported in other trials of patients with femoropoliteal disease (range 65% to 83%). 10, [21] [22] [23] This finding reflects the difficulty of obtaining angiograms in patients who have few or no symptoms. Although in the present study more patients than expected did not perform control angiography, the reduction in diameter stenosis after PEB and stenting was significant as compared with other treatments investigated. Thus, the actual improvement after PEB and stenting was even higher than expected according to the sample size calculation. Another limitation is that operators, patients, and staff were not blinded to treatment assignments, and introduction of bias based on knowledge of assigned treatment cannot be excluded. However, the independent core laboratory was blinded to the treatment assignment.
A previous meta-analysis showed that in femoropopliteal disease, both PEB angioplasty and stenting have superior antirestenotic efficacy compared with BA without safety issues. 24 Our study adds that combination of PEB and stenting further decreases restenosis. Because the first results with paclitaxel-eluting stents showed improved revascularization rates compared with bare metal stents, a therapy with PEB and stenting may represent a valuable alternative. In addition, the combination of PEB and stenting does not preclude the option of using PEB as a stand-alone therapy in case of optimal angiographic result after dilation. 19 Moreover, cost-effectiveness of PEB and stenting compared to paclitaxel-eluting stents needs to be examined in future studies. PEB has superior efficacy as compared to BA. 25 Whether PEB has superior efficacy as compared to paclitaxel-eluting stents remains to be further assessed. Values are mean±SD or n (% Kaplan-Meier estimates). There was no requirement for bypass surgery or amputation of the target limbs throughout the study period. *P<0.017 using a log-rank test. Figure 2 . Two-year freedom from target lesion revascularization.
Kaplan-Meier curves of patients assigned to PEB and stenting (black line), BA and stenting (green line), or DA (red line). BA indicates balloon angioplasty; DA, directional atherectomy; PEB, paclitaxel-eluting balloon; SFA, superficial femoral artery; and TLR, target lesion revascularization.
